Memolan (Memantine Hydrochloride)

Memantine hydrochloride acts as a non‑competitive antagonist of the NMDA receptor, reducing excessive glutamate‑mediated calcium influx and thereby limiting excitotoxic neuronal damage that contributes to cognitive decline in Alzheimer’s disease.

The dosage of Memolan is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, and tolerability. Specific dosing regimens should be obtained from a qualified healthcare professional.

Safety data for memantine hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Memolan (memantine) belongs to the NMDA receptor antagonist class, differing from cholinesterase inhibitors such as donepezil. While cholinesterase inhibitors enhance acetylcholine activity, memantine reduces glutamate‑induced excitotoxicity, and it is typically used in moderate to severe stages or when patients cannot tolerate cholinesterase inhibitors.

Memolan should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Memolan is taken orally, usually once daily, with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include seizures, cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, hepatic dysfunction, and emergent suicidal thoughts. Patients should be monitored regularly for any of these adverse events and seek immediate medical attention if they occur.

Memolan is contraindicated in patients with known hypersensitivity to memantine or any of its excipients, and it should be used with caution in individuals with severe renal impairment, uncontrolled seizures, or those taking other NMDA antagonists. A healthcare professional should evaluate suitability before initiating therapy.